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Background: SARS-CoV-2 infection causes severe pneumonia (COVID-19), but the 
mechanisms of subsequent respiratory failure and complicating renal and myocardial 
involvement are poorly understood. In addition, a systemic prothrombotic phenotype has been 
reported in COVID-19 patients. 
Methods: A total of 62 subjects were included in our study (n=38 patients with RT-PCR 
confirmed COVID-19 and n=24 non-COVID-19 controls). We performed histopathological 
assessment of autopsy cases, surface-marker based phenotyping of neutrophils and platelets, and 
functional assays for platelet, neutrophil functions as well as coagulation tests.   
Results: We provide evidence that organ involvement and prothrombotic features in COVID-19 
are linked by immunothrombosis. We show that in COVID-19 inflammatory microvascular 
thrombi are present in the lung, kidney, and heart, containing neutrophil extracellular traps 
associated with platelets and fibrin. COVID-19 patients also present with neutrophil-platelet 
aggregates and a distinct neutrophil and platelet activation pattern in blood, which changes with 
disease severity. Whereas cases of intermediate severity show an exhausted platelet and 
hyporeactive neutrophil phenotype, severely affected COVID-19 patients are characterized by 
excessive platelet and neutrophil activation compared to healthy controls and non-COVID-19 
pneumonia. Dysregulated immunothrombosis in SARS-CoV-2 pneumonia is linked to both 
ARDS and systemic hypercoagulability.  
Conclusions: Taken together, our data point to immunothrombotic dysregulation as a key 
marker of disease severity in COVID-19. Further work is necessary to determine the role of 
immunothrombosis in COVID-19. 
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Non-standard Abbreviations and Acronyms: 
ARDS: acute respiratory distress syndrome 
COVID-19: Corona Virus Disease 2019 
DIC: Disseminated Intravascular Coagulation  
ECG: Electrocardiogramm 
GFR: Glomerular Filtration Rate 
NETosis: neutrophil extracellular trap formation 
PMN: Polymorphonuclear Cells 
RT-PCR. Reverse Transcriptase Polymerase Chain Reaction 














Clinical Perspective  
 
What is new?  
• Dysregulated platelets and neutrophils cooperate to drive a systemic prothrombotic state 
in SARS-CoV-2 infection, indicating inflammation as trigger for thrombotic 
complications frequently observed during COVID-19.  
• Microvascular thrombi containing neutrophils, platelets, and Neutrophil Extracellular 
Traps (NETs) are a hallmark of severe SARS-CoV-2 infection, linking multi-organ 
failure and systemic hypercoagulability in COVID-19. 
 
What are the clinical implications?  
• SARS-CoV-2 infected patients are at increased risk for thrombotic events, making 
prophylactic anticoagulation and vigilant monitoring for thrombotic complications a 
central task in management of COVID-19 patients. 
• Targeting immunothrombosis or NETosis by modulating platelet-neutrophil interactions 
could be a valuable therapeutic approach for respiratory failure and thrombotic 


















The COVID-19 pandemic is a global health care challenge, with rapid spread, high 
contagiousness and an approximate case fatality rate of 1.0-2.3%1-4. However, due to the lack of 
specific treatment, therapy has so far mainly been limited to supportive care4-6.  
Although acute respiratory distress syndrome (ARDS) is the central feature of disease 
severity, non-pulmonary organ damage has emerged as an important predictor of mortality7. 
Patients hospitalized for COVID-19 are at high risk for kidney failure and myocardial 
involvement is common in severe cases, both correlating with poor outcome8-10. The underlying 
mechanisms of COVID-19 pulmonary and non-pulmonary tissue injury are insufficiently 
understood11.  
Preliminary data point to a prothrombotic state in COVID-19 patients12, with a possible 
beneficial effect of heparin. However, a thorough analysis of cellular and plasmatic coagulation 
of affected patients is missing13-15. In particular, it is unclear whether and how the inflammatory 
response to SARS-CoV-2 and its associated coagulopathy are intertwined. Recent evidence from 
translational and basic research has established the concept of immunothrombosis, a process that 
integrates innate immunity, platelets and clotting factors to capture and fight invading pathogens 
but also contributes to inflammation-related tissue damage16, 17.  
In this study, we provide first evidence that neutrophils, immunogenic platelets, and a 
dysregulated coagulation cascade cooperate to propagate immunothrombotic tissue injury in 
COVID-19, as shown in autopsy specimens and the blood of patients. Our data show distinct 
neutrophil and platelet activation states and increased plasmatic coagulation in COVID-19, all of 














The data that support the findings of this study are available from the corresponding author upon 
reasonable request. A total of 62 subjects were included in our study (n=38 patients with RT-
PCR confirmed COVID-19 and n=24 non-COVID-19 control groups). The study design is 
outlined in (Fig. Ia-e in the Supplement).  Patients with severe pre-existing kidney or liver 
dysfunction, severe autoimmune diseases, immunosuppression, chronic infection, patients 
requiring ECMO therapy, with a known coinfection with Influenza or Respiratory Syncytial 
Virus (RSV) and patients receiving antiplatelet medication were excluded. COVID-19 patients 
were divided into a group of severe cases requiring intubation and intensive care treatment 
(CoV_sev, n=18), and a group of intermediate severity (CoV_int, n=20), which were 
hospitalized and either required no oxygen or received non-invasive supplemental oxygen. 
Horowitz Indices (paO2/FiO2) of CoV_sev patients were directly derived from ventilation 
parameters. For CoV_int, Horowitz index was calculated from non-invasive oxygen support 
(FiO2 approximation) and pulse oximetry (paO2 approximation)18.   
Flow cytometric phenotyping and platelet/coagulation testing 
31 patients with COVID-19, 5 patients with non-COVID-19 pneumonia and 10 age-matched 
control patients without pulmonary pathology were included for flow cytometry, ROTEM and 
PFA analyses. Baseline characteristics of the flow cytometric phenotyping and 









analysis was performed with blood from 11 intermediate and 5 severe COVID-19 patients, 
whereas platelet function testing, whole blood impedance blood aggregometry, and rotational 
thrombelastometry were performed on blood from 9 intermediate and 8 severe COVID-19 
patients, with an overlap of two severe COVID-19 patients. To avoid batch effects, principle 
component analysis, t-SNE based dimension reduction and automated clustering was performed 
in n=7 controls, n=4 non-COVID-19 pneumonia, n=5 CoV_sev and n=11 CoV_int patients 
sampled and analyzed within 10 days.  
Histopathological assessment 
One patient, aged 91 years, showed a typical disease course, declined intensive care treatment 
and was autopsied after developing progressive ARDS and succumbing to the infection on the 
seventh day after hospitalization (see details in Results and Fig. 1a-b). For quantification of 
immunothrombosis /NETosis, lung specimens from 4 additional deceased patients with RT-PCR 
confirmed COVID-19 (Age (Median= 78, IQR 69-86); Male (N=3, 60%)) were included, as well 
as five patients, who had died from cardiovascular events without lung involvement. One lung 
autopsy specimen was from a deceased COVID-19 patient who was also included in the flow 
cytometric phenotyping as a severe COVID-19 patient. 
In vitro assays 
We used peripheral blood from 3 additional RT-PCR confirmed COVID-19 patients requiring 
ICU care (Age (Median=77, IQR= 67-81); Male (N=1, 33%)) and 5 healthy control patients, 
with an overlap of one control patient with the flow cytometric analysis, for in-vitro analysis of 
platelet activation assay neutrophil isolation, assessment of steady-state activation and induction 









In accordance with the Declaration of Helsinki, and with the approval of the Ethics 
Committee of Ludwig-Maximilian-University Munich, informed consent of the patients or their 
guardians was obtained. COVID-19 patients are part of the COVID-19 Registry of the LMU 
University Hospital Munich (CORKUM, WHO trial ID DRKS00021225). Pseudonymized data 
was used for analysis, the study was approved by the ethics committee of LMU Munich (No: 20-
245 and 19-274). 
Histopathology 
Histopathology and immunofluorescence stainings were performed on paraffin-embedded heart, 
lung and kidney specimens of the autopsy specimen described in Figure 1. Hematoxylin-Eosin 
(HE) and Van Gieson's (EvG) stainings were performed as previously described19. For 
immunofluorescence staining, specimens were deparaffinized and subsequently stained using a 
published protocol19. For histological quantification we used 4 additional lung autopsy 
specimens from COVID-19 deceased patients, and 5 lung autopsy specimens of patients 
deceased from cardiovascular events without lung involvement. Used antibodies were anti-
Myeloperoxidase (MPO), anti-citrullinated histone H3, anti-fibrinogen, anti-CD42b and Hoechst 
33342 for immunofluorescences, as well as anti-Fibrin and anti-CD42b for 
immunohistochemistry. Slides were visualized using either Airyscan technology (Zeiss LSM 
880), epifluorescence microscopy (Zeiss) or Vectra Polaris system. The 3D reconstruction was 
rendered with Imaris. For quantification of NETs and microthrombi, blood vessels were defined 
as tubular or circular enclosed structures with DAPI-positive endothelial lining and visible 
elastica interna as well as lack of ciliated epithelium and a lack of obvious communication with 
alveoli. Intravascular cells were regarded as neutrophils if they stained positive for DAPI and 









stained MPO+ and citH3+ as well as DAPIint/high. Vessels were considered to contain 
immunothrombotic occlusions if there was a (partial) occlusion of the vessel lumen that stained 
positive for a network of fibrinogen, neutrophils (MPO) and platelets (CD41) (see Fig. IIa in the 
Supplement). The mean of 3 high power fields for each patient without massive lung damage or 
hepatization was used. Quantification was performed with ImageJ v2.0.0-rc-69. 
Platelet and neutrophil phenotyping 
Blood samples were obtained either from a peripheral vein or an arterial line. 2 ml of patient 
blood was mixed with a Lysing-PFA-Fixation solution containing 300 µl Heparin, 15.7 ml 
distilled water and 2 ml FACS Lysing Solution 10x (BD Biosciences), containing formaldehyde 
and diethylene glycol. Blood was incubated for at least one hour to ensure complete virus 
inactivation and lysis of the red blood cells. Lysates were then centrifuged (400 G/7 min) and the 
resulting pellets were resuspended in 400 µl PBS containing 0.5% BSA. 50 µl of the suspension 
was incubated with 50 µl of the antibody panel (Table II in the Supplement) for 20 minutes at 
room temperature. Measurements were performed on a BD LSRFortessa Flow Cytometer. 
Analysis was performed using FlowJo Software (FlowJo v. 10.6.1, BD).  
After down-sampling twice with Downsample v3 plugin and two concatenation steps, t-
Distributed Stochastic Neighbor Embedding (t-SNE) of an equal and representative number of 
cells per group was performed using the t-SNE FlowJo plugin. Subpopulations detection was 
performed by applying the Phenograph algorithm (Phenograph Plugin for FlowJo)20, the 
resulting Phenograph clustering was then used to assign the neutrophil and platelet 
subpopulations. The principal component analysis and heatmaps were created using the ClustVis 
algorithm21. All mean fluorescence intensities (MFIs) reported are relative MFIs (percent of 









clustering was performed via correlation distance, average clustering with tightest cluster first for 
rows and Manhattan distance, complete clustering and higher mean value first for columns or 
with no clustering for columns. Hyporeactive neutrophils were defined as decreased expression 
of naïve-neutrophil marker L-selectin (CD62L), adhesion receptors CD11b and CD49d as well 
as FcγRIII (CD16). Exhausted platelets were defined as platelets that show a low expression of 
CD40L, as well as low activation marker exposure. 
In-vitro assay 
Blood from 3 COVID-19 patients with severe disease (CoV_sev) and 5 control donors (Ctrl) was 
used for in-vitro assays. Flow cytometric measurements were performed on a BD LSRFortessa 
Flow Cytometer. Analysis was performed using FlowJo Software (FlowJo v. 10.6.1, 
BD). Histological analysis was performed with ImageJ v2.0.0-rc-69. 
Platelet activation assay 
Human platelets were isolated from citrated whole blood as described previously 22, labeled 
antibodies against CD62P (BioLegend, Cat. 304925) and PAC-1 (BioLegend, 362806) and 
subsequently exposed to Thrombin (0.01 and 0.1 U/ml), Convulxin (0.1 µg/ml), ADP (10 µM), 
Collagen (20 µg/ml) or NaCl (Unstimulated) for 20 min at RT. After fixation with 
paraformaldehyde (PFA, 1% final concentration), degranulation and integrin IIbIIIa activation 
were assessed by measuring mean fluorescent intensities of CD62P and PAC-1. 
Neutrophil isolation and assessment of steady-state activation 
Whole blood was drawn from CoV_sev patients (n = 3) and healthy donors (n = 5) into EDTA-
containing vials. Neutrophil granulocytes were isolated using magnetic beads (EasySep® Direct 
Human Neutrophil Isolation Kit, Stemcell Technologies, Cat. #19666) according to 









(VI 0.4) coated with poly-L lysine (Sigma) by brief centrifugation (40G, 5 min), washed with 
PBS three times and then fixed with 1% PFA (10 min). Cells were permeabilized (0.5% triton X-
100, 10 min) and stained with anti-myeloperoxidase (MPO, R&D Systems AF3667), anti-
citrullinated histone H3 (abcam ab5103) and Hoechst dye for 30 min. Cells were visualized by 
immunofluorescence microscopy (6 fields of view at 40x magnification per replicate), and the 
number of activated neutrophils defined by citr. H3-positive nuclei as well as extracellular citr. 
H3/MPO-positive foci were assessed.  
Induction of NETosis with platelet-rich plasma 
Neutrophils from a healthy donor were isolated using  a Ficoll-Paque gradient (GE Healthcare) 
according to manufacturer’s instructions and seeded onto Ibidi® µ-Slides (VI 0.4) coated with 
poly-L lysine (Sigma) by brief centrifugation (40G, 5 min). Platelet-rich plasma (PRP) from 3 
CoV_sev patients and 5 healthy donors was isolated as described previously22, stimulated with 
2.3 mM calcium chloride and 20 µM ADP and subsequently added to the seeded neutrophils for 
20 min (37°C, 5% CO2). Neutrophil-platelet aggregates were fixed with 1% PFA (10 min), 
permeabilized using 0.5% triton X-100 (10 min) and stained with anti-MPO, anti-citr. H3, anti-
CD41 antibodies (HIP8 clone, Biolegend) and Hoechst dye to counterstain nuclei. NETosis and 
neutrophil-platelet interaction were visualized by immunofluorescence microscopy (six fields of 
view at 40x magnification per replicate). NETosis was defined according to the criteria 
mentioned above (see Methods Histopathology). 
Neutrophil activation assay by flow cytometry 
50 µl of whole blood from CoV_sev (n = 3) and healthy controls (n = 5) were incubated with 2.3 
mM calcium chloride and 50 nM phorbol myristate acetate (PMA) or DMSO (Ctrl), for 20 min 









for neutrophil activation (CD11b, CD62L, CD63, CD15, Biolegend) for 10 min, lysed and fixed 
with 400 FACS Lysing buffer and subsequently analyzed by flow cytometry (BD LSRFortessa 
Flow Cytometer, data analysis with FlowJo v. 10.6.1, BD). 
Platelet and coagulation testing 
Platelet and coagulation testing were performed in a subset of included patients. We used the 
Platelet Function Analyzer (INNOVANCE PFA 200 System, Siemens Healthineers) to assess 
platelet function under high shear conditions, mimicking primary hemostasis in the arterial 
system. Briefly, blood was flown through a cartridge containing a membrane either coated with 
collagen/epinephrine (PFA-EPI) or collagen/ADP (PFA-ADP). Platelet clotting was quantified 
by measuring closure times by standardized whole blood impedance blood aggregometry 
(Multiplate Analyzer, Roche Diagnostics) to assess platelet function in Hirudin-anticoagulated 
blood, excluding a contribution of fibrin formation in this setup. Briefly, changes in impedance 
after addition of platelet agonists ADP and Thrombin Receptor Activating Peptide (TRAP) were 
used to assess platelet aggregation over time, readout is standardized by assessing Area under the 
curve (AUC). In addition to standard INR and aPTT measurements, we performed enhanced 
analysis of platelet-coagulation interplay and clot-formation under low-shear condition using 
rotational thrombelastometry (ROTEM, Tem Innovations). This viscoelastic method allows the 
quantification of the dynamics and thrombus properties during clot-formation and lysis. Briefly, 
citrate-anticoagulated blood was recalcified and clot formation was initialized by adding start 
substances activating the intrinsic system (INTEM) or the extrinsic system (EXTEM). A possible 
effect of heparin was excluded by repeating the INTEM in the presence of Heparinase 
(HEPTEM). To exclude platelet contribution to clotting, actin-inhibitor Cytochalasin D was 









All materials used were obtained from the manufacturer, and all the platelet/coagulation 
function testing was performed according to published standard protocol in an accredited 
laboratory setting according to DIN EN ISO 15189. 
Data analysis and statistics 
Data was analyzed using Excel v.16 (Microsoft) and Prism v. 8.3.0. (GraphPad) software. 3D 
reconstructions of z-stack data were performed using Imaris (Bitplane). The principal component 
analysis and heatmaps were created using ClustVis (Flow cytometric analysis for details). Adobe 
Illustrator was used to assemble the graphical illustrations. Results are shown as mean ± s.e.m., 
unless otherwise indicated. For direct comparisons between two groups, unpaired, two-tailed 
Student’s t-tests were used, or in case of platelet and IL-6 time-courses paired t-tests. For 
comparisons between groups either non-parametric Kruskal-Wallis-tests or two-way ANOVAs 
were used. A post-hoc Dunn's or Dunnett's multiple comparisons test to the control column (Ctrl) 
was used. For clarity, only post-hoc test results are displayed in the graphs. If the Kruskal-Wallis 
or ANOVA test showed a difference between groups without a significant post-hoc test, a bar 
over the graph indicates the ANOVA/Kruskal-Wallis p value. P values of ≤0.05 are considered 
significant and denoted with *, ≤0.01 with ** and ≤0.001 with ***. Individual patients are 
represented as dots, unless otherwise indicated. Reference ranges for laboratory values as used at 
the patient’s hospital, if available, are shown as gray boxes. If there were different reference 
ranges for male and female patients, the mean of the two was taken as the reference range. For 
all regression analyses, black lines represent best-fit line, gray area the 95% confidence interval. 











Results & Discussion 
We sought to explore tissue injury in COVID-19 by studying histopathological autopsy 
specimens from a deceased patient with RT-PCR-confirmed SARS-CoV-2 infection and typical 
findings of COVID-19 pneumonia on CT scans. The patient developed progressive respiratory 
failure (Horowitz Index, paO2/FiO2 at admission: 457; 6 days later: 132, ref. range > 300), signs 
of cardiac injury without ECG evidence for macrovascular thrombosis (high-sensitive troponin T 
concentration 0.798 pg/ml, ref. range < 0.014 ng/ml), kidney failure (glomerular filtration rate 43 
ml/min, GFR decrease from admission: 27%) and dysregulated coagulation (D-dimer 3.9 µg/ml, 
ref. range < 0.5 µg/ml) over the course of the disease (Fig. 1a-b). Hematoxylin-Eosin staining 
revealed the formation of microvascular clots in the lung in the absence of pulmonary embolism, 
similar to observations in lung samples of patients suffering from SARS-CoV-1 infection during 
the SARS epidemic 2003 (Fig. 1c-d)23. In addition to platelets and fibrin (Fig. 1d), these thrombi 
contained large numbers of granulocytes (Fig. 1c inset).  
We and others have shown that under certain inflammatory conditions, platelets, 
neutrophils (abbreviated as PMN) and the coagulation cascade team up to contain invading 
pathogens, a process termed immunothrombosis16, 24, that can aggravate tissue damage by 
triggering vessel occlusion and hypoxia25. 
To further explore the contribution of immunothrombosis to the pathogenesis of COVID-
19, we used immunofluorescence to define the cellular and molecular composition of the 
microthrombi. We confirmed the presence of neutrophils in the microthrombi, embedded in the 
fibrin clot (Fig. 1e). We verified this finding in an additional four COVID-19 cases. Here, we 
observed strongly increased numbers of granulocyte-containing thrombi in COVID-19 autopsies, 









and Fig. IIa in the Supplement). Confocal microscopy revealed numerous intravascular 
neutrophils in close association with platelets and fibrin (Fig. 1g). Interestingly, these neutrophil-
enriched depositions were not restricted to the lung but were also present in renal and cardiac 
microvessels (Fig. 1g). This led us to hypothesize that dysregulated immunothrombosis driven 
by activated neutrophils and immunogenic platelets might contribute to organ injury and a 
systemic thrombogenic state in COVID-19. 
 We therefore assessed neutrophil dynamics and activation state in two hospitalized 
COVID-19 cohorts of defined disease severity: (1) severe cases requiring intubation and 
intensive care treatment (CoV_sev, n=19), and (2) a group of intermediate severity (CoV_int, 
n=20), which either required no oxygen or received non-invasive supplemental oxygen (Fig. Ia-b 
in the Supplement). Severe cases showed higher peripheral neutrophil counts, correlating with 
the degree of lung injury as assessed by the Horowitz Index (Fig. 2a-b).  
To gain insight into neutrophil activation patterns in COVID-19, we used a comprehensive high-
dimensional flow cytometric activation marker analysis and subsequent t-SNE dimension 
reduction. Comparing non-COVID-19 pneumonia (Ctrl_pneu) and patients without signs of 
infection (Ctrl) with CoV_int and CoV_sev cases, we identified distinct activation states (Fig. 
2c-d, Table II in the Supplement, Fig. IIb-e in the Supplement and Methods). To characterize the 
markers responsible for the COVID-19 neutrophil phenotypes, we employed unsupervised 
clustering and subsequent gating of six neutrophil polarization states (PMN1-PMN6, Fig. 2e-f 
and Fig. IIIa-c in the Supplement). Interestingly, we found PMN3 sub-cluster to be significantly 
enhanced in CoV_int cases. This sub-cluster showed a decrease in naïve-neutrophil marker L-
selectin (CD62L), and adhesion receptors CD11b and CD49d26, 27. Also, FcγRIII (CD16) 









downregulated (Fig. 2f and Fig. IIId in the Supplement)27. Therefore, the PMN3 profile points to 
hyporeactive and apoptotic neutrophils in the circulation of CoV_int patients, possibly reflecting 
the outcome of neutrophil recruitment and activation in the lung vasculature. In contrast, 
activation marker CD177 was globally upregulated in severe COVID-19 cases (Fig. IIId in the 
Supplement), and the highly activated subpopulation PMN6 was overrepresented in CoV_sev 
(32.1 ±12.9% of neutrophils in CoV_sev, vs. 8.8 ±3.3% in controls, Fig. 2f). CD177 furthermore 
correlated significantly with pulmonary disease severity, underlining a potentially causative role 
of neutrophils (Fig. 2g). Isolation and staining of peripheral blood neutrophils from CoV_sev 
patients showed increased activation of these cells in the circulation compared to controls (Fig. 
2h). In line, in vitro stimulation of CoV_sev neutrophils with phorbol myristate acetate (PMA) 
revealed a differential response with increased CD63 expression indicating granule release, and 
decreased expression of adhesion receptor CD11b in COVID-19 compared to controls (Fig. IIIe 
in the Supplement). In summary, distinct neutrophil signatures exist in different courses of 
COVID-19 ranging from a hyporeactive phenotype in intermediate COVID-19 patients to an 
excessive, global neutrophil activation characterizing severe COVID-19. Platelets are major 
initiators of neutrophil activation and boost neutrophil-driven tissue damage22. Indeed, in 
COVID-19 patients formation of circulating platelet-neutrophil-aggregates, a key element of 
immunothrombosis24, correlated in a linear fashion with pulmonary disease severity (Fig. 2i).  
Given the central role of platelets driving immunothrombosis22, 28, we analyzed 
quantitative and qualitative changes of platelets. In COVID-19, thrombocytopenia at hospital 
admission is reported in more severe cases, hinting at platelet consumption29. In line with this 
notion, platelet counts in our cohort of COVID-19 patients were at the lower end of the normal 









revealed highly dynamic changes over time, particularly in patients admitted to ICU and 
requiring intubation (Fig. 3b). When assessing individual platelet levels, 81% of COVID-19 
patients showed an increase (50% or more) during hospital stay (21/26 patients, Fig. 3c), and 
50% of patients even developed mild thrombocytosis (platelet count >360.000/µl, 13/26 
patients). Interleukin-6 (IL-6) has been causally linked to TPO transcription and increased 
thrombopoiesis30. We correlated IL-6 plasma levels and platelet counts in CoV_sev and CoV_int 
patients (Fig. 3b). In severe cases, IL-6 peaked at the time of intubation/ICU admission and was 
followed by a peak in platelet count with a lag of five days (Fig. 3b-c). We observed a similar 
trend in the intermediate cohort (Fig. IVb in the Supplement), indicating a link between the acute 
phase inflammatory response and a reactive increase in platelet production in COVID-1931-33. 
Hematocrit levels of CoV_int and CoV_sev patients decreased over the disease course, 
excluding dehydration as the reason for increased platelet count (Fig. IVc in the Supplement). 
To assess whether this quantitative shift in the platelet compartment was accompanied by 
phenotypic changes, we employed comprehensive antibody-based surface marker analysis (Fig. 
Va-b in the Supplement, Table III in the Supplement, Methods). We performed t-SNE based 
unsupervised clustering, which uncovered distinct changes in platelet marker profiles in 
intermediate and severe COVID-19 cases, compared to both non-COVID-19 pneumonia patients 
and patients without signs of infection (Fig. 3d-e and Fig. Vb in the Supplement). We confirmed 
this finding using Principal Component Analysis, which revealed distinct platelet activation 
patterns with a strong correlation to disease severity (Fig. Vc-d in the Supplement). To gain 
insight into these distinct marker profiles, we performed clustering of platelet populations in a 
robust manner (unsupervised clustering with Phenograph followed by subsequent supervised 









of 10 identified sub-clusters were significantly enriched in CoV_int (Plt9 and Plt10), and one out 
of 10 populations was enriched in CoV_sev (Plt4) (Fig. 3g, Fig. VIb-c in the Supplement). All 
COVID-19 enriched clusters as well as global expression analysis (Fig. VId in the Supplement) 
showed downregulation of scavenger receptor CD36 and transmembrane protein CD40L in 
comparison to control patients. 
In CoV_int patients, an expression heatmap revealed generalized downregulation of 
platelet adhesion receptors, including CD41, CD31 and PSGL-1. In addition, Toll-like receptor 4 
(TLR-4) and C-X-C Motif Chemokine Receptor 4 (CXCR4), which have been implicated in 
platelet host defense25, were decreased. Compared to control cohorts, markers of platelet 
activation such as CD63, activated integrin GPIIbIIIa (PAC-1) and CD62P were downregulated 
or detected at similar levels in CoV_int (Fig. VId in the Supplement).  
In contrast, we identified a small but highly activated platelet population in some CoV_sev 
patients (Plt1, 10.0% ±4.5 of platelets in CoV_sev, vs. 3.1% ±0.7 in controls, Fig. 3g). Plt4 
subcluster, which was enriched in CoV_sev, showed low expression of GpIIbIIIa and CD36, 
comparable to CoV_int clusters, but exhibited a higher level of activation of immune receptors 
like CLEC-2 (Fig. 3g), which also applied to the composite platelet heatmap (Fig. Vd in the 
Supplement). 
 The overall hyporeactive phenotype in peripheral blood, in combination with evidence of 
recruitment to the pulmonary, renal, and cardiac microvasculature, suggested platelet activation 
within the microvasculature and subsequent circulation of exhausted platelets, in line with our 
data on neutrophils. Indeed, after activation and sequestration in the lung, exhausted platelets 









mediate platelet-leukocyte interaction as well as decreased scavenger receptor CD36 densities 
can be explained by activation and receptor shedding in the pulmonary vasculature37, 38.  
As these data suggest a profound impact of COVID-19 on peripheral platelet function, we next 
assessed primary hemostasis under high shear conditions using the PFA-200 system (Fig. 3h, see 
Methods). CoV_int patients showed normal response to Collagen-Epinephrine as well as 
Collagen-ADP matrices. In CoV_sev, we found increased plug formation in both tests compared 
to CoV_int (Fig. 3h). This might be caused by the aforementioned highly activated Plt1 
subpopulation present in CoV_sev patients.  
Whole-blood impedance aggregometry showed mild reduction in platelet aggregation in 
COVID-19, with 41% of patients (7/17) below reference range following adenosine diphosphate 
(ADP) stimulation (Fig. 3i). This finding was mainly driven by hyporeactivity of CoV_int cases 
in response to ADP and thrombin-receptor agonist TRAP, with a less pronounced effect in 
CoV_sev. In a separate experiment, we measured platelet activation upon stimulation with 
various agonists, which confirmed a dysregulated platelet phenotype in severe COVID-19, 
showing hyperreactivity towards weak agonists with a decreased maximal response towards 
strong agonists (see Fig. VIe in the Supplement). In conclusion, platelet function analysis 
uncovered normal to (mildly) reduced platelet responses in CoV_int cases, in accordance with 
the hyporeactive platelet phenotype revealed by expression analysis. In CoV_sev patients, we 
revealed a more complex activation pattern with signs of thrombogenic hyperreactivity and 
immunologic exhaustion.  
 Next, we defined whether changes in neutrophil and platelet activation are associated 
with changes in systemic plasmatic coagulation parameters in COVID-19 patients. In our cohort, 









published, intermediate and severe COVID-19 patients exhibited elevated plasma fibrinogen, 
with almost 90% above reference range (27/31 patients, Fig. 4b)14. Interestingly, fibrinogen 
levels correlated significantly with Horowitz Index (paO2/FiO2), a surrogate parameter for 
classification of ARDS severity (Fig. 4c). Ferritin, another acute phase protein previously 
described to be associated with COVID-19 severity, correlated to lesser extent (Fig. VIIa in the 
Supplement). This could hint at a specific effect of SARS-CoV-2 on fibrinogen plasma levels 
beyond the canonical acute phase response. Along these lines, the related strain SARS-CoV-1, 
the causative coronavirus in the 2003 SARS outbreak, was reported to directly upregulate 
fibrinogen expression in infected cells39.   
We also found fibrin degradation product D-Dimer to be strongly elevated in COVID-19 
(mean 1.93 pg/ml), with 65% (13/20 patients) of CoV_int and all (11/11 patients) CoV_sev 
patients above reference range (Fig. 4d), pointing to constant activation of the coagulation 
cascade in COVID-19 patients. In addition, D-Dimer also correlated significantly with disease 
severity (Fig. VIIb in the Supplement). 
Two important causes of elevated D-Dimer are disseminated intravascular coagulation 
(DIC) and macrovascular thrombosis, both complications of COVID-1915, 40. However, normal 
to elevated platelet counts and elevated fibrinogen, in combination with normal aPTT and INR, 
excluded DIC in our cohort. All CoV_sev patients received prophylactic heparin treatment, and 
no event of macrovascular thrombosis (defined as stroke, myocardial infarction, or venous 
thromboembolism) was diagnosed at the time of enrollment in this closely monitored ICU 










To more specifically assess platelet-coagulation interplay and clot-formation under low-
shear conditions, we employed rotational thrombelastometry (ROTEM). Intrinsic (INTEM) and 
extrinsic (EXTEM) activation of clot formation revealed clot formation times (CFT), maximal 
clot firmness (MCF) and clotting times (CT) within the reference range for non-severe CoV_int 
cases (Fig. 4e-f, Fig. VIIc in the Supplement). Addition of heparinase (HEPTEM) to exclude a 
possible heparin-mediated effect showed similar MCF and CFT results (Fig. VIId in the 
Supplement). However, in CoV_sev patients, MCF was significantly increased, and CFT 
shortened compared to CoV_int (Fig. 4e and 4f). INTEM and EXTEM clot formation correlated 
with neutrophil counts as well as disease severity, exhibiting decreased clot formation time and 
increased clot firmness in more severe cases (Fig. 4g and Fig. VIIe-g in the Supplement). 
Clotting time (CT) was within reference range and did not differ between CoV_int and CoV_sev, 
indicating that clotting factors are not the main drivers of the differences in MCF and CFT (Fig. 
VIIc in the Supplement). Following clot formation, maximum lysis (ML) of clots was also 
reduced in CoV_sev, and clot resistance to lysis correlated strongly with disease severity (Fig. 
4h-i).  
Lastly, we excluded platelet contribution to clot formation by addition of actin 
polymerization inhibitor Cytochalasin D. This revealed platelet independent heightened 
plasmatic clot formation (FIBTEM) in severe and intermediate cases, with 53% above reference 
range for maximal clot firmness (MCF, 9/17 patients, Fig. 4j). We hypothesized that increased 
clot formation might be, in part, caused by the considerably elevated fibrinogen plasma 
concentrations in COVID-19. Indeed, plasma concentrations of fibrinogen and FIBTEM MCF 









In summary, plasmatic coagulation is skewed towards a procoagulant state correlating 
with disease severity, reflected by peripheral blood coagulation tests as well as histopathological 
evidence of microvascular thrombosis in affected organs.  
Mechanistically, we uncovered dynamic quantitative and qualitative changes in 
neutrophil and platelet compartments in COVID-19, in addition to histopathological and flow 
cytometric evidence of a partnership between these two cell types. Platelets are known to 
regulate neutrophil recruitment42. In particular, activated platelets have been shown to be 
critically involved in neutrophil extracellular trap (NET) formation, a central element of 
immunothrombosis24, 43, 44. NETs have high procoagulant potential, and could therefore serve as 
a link to explain altered blood coagulation and microvascular thrombosis in SARS-CoV-2 
infection45. Indeed, elevated markers of NETosis have been found in COVID-19, correlating 
with disease severity46. 
To underline our hypothesis that partnership of neutrophils and dysregulated platelets 
drives NET formation and thereby possibly immunothrombosis in COVID-19, we superfused 
neutrophils isolated from healthy donors with activated platelet rich plasma from either CoV_sev 
or control patients (Fig. 4l). Platelets from severe COVID-19 patients showed increased adhesion 
to neutrophils (Fig. 4m, Fig. VIIh in the Supplement), and resulted in enhanced NET formation, 
underlining the mechanistic link of immunogenic platelets driving neutrophil activation in 
COVID-19 (Fig. 4n, Fig. VIIi in the Supplement). 
Finally, we re-analyzed tissue sections for the presence of microvascular NETs. Indeed, 
we discovered frequent intravascular NETs derived from neutrophils in the pulmonary 
vasculature, which were found to be virtually absent in control lungs (Fig. 4o and p). 








kidney and heart specimens (Fig 4q and r). These structures were also spatially associated with 
fibrin deposition, underlining their procoagulant role (Fig. 4o and p). 
Taken together, we provide evidence that platelets, neutrophils, and the coagulation 
cascade are drivers of disease severity and might prove to be valuable pharmacological targets in 
COVID-19 (Fig. VIII in the Supplement, Graphical abstract). In addition, SARS-CoV-2 infected 
patients are at risk for increased thrombotic events, making prophylactic anticoagulation and 
vigilant monitoring for thrombotic complications a central task in management of COVID-19 
patients. 
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Figure 1. COVID-19-associated coagulopathy in the lung, kidney and heart presents as 
microvascular immunothrombosis. a, COVID-19 disease progression of autopsy case. 
Horowitz oxygenation index (paO2/FiO2), as well as Interleukin 6 (IL-6), high-sensitive 
Troponin T and glomerular filtration rate (GFR) are plotted. b, Axial and coronal computed 
tomographic (CT) scans of the chest of the patient at presentation with COVID-19 defining 
bipulmonary infiltrates and ground glass opacities. c, Hematoxylin Eosin (HE) staining of a 
pulmonary microthrombus. Immune cells, most notably cells with segmented nuclei, can be 
observed in the thrombus (black arrows). d, Elastica van Gieson, fibrinogen and platelet 
(CD42b) immunohistochemistry of the lung microthrombus. e, Exemplary immunofluorescence 
of a cut through a lung microthrombus showing of neutrophils (MPO) and fibrinogen. Dashed 
lines indicate vessel borders. Scale bars=100 µm. f, Percentage of vessels with 
immunothrombosis (platelets, fibrinogen, neutrophils) in the lung vasculature. n=5 controls, n=5 
COVID-19 autopsy cases. Two-tailed unpaired t-test. g, Immunofluorescence staining of 
intravascular microthrombi with spatial association of neutrophils (MPO), platelets (Plt, CD42b) 
and fibrin. Scale bars: 10 µm, dashed lines indicate vessel borders. ** p<0.01. 
Figure 2. High dimensional analysis of neutrophil markers reveals a distinct neutrophil 
signature, characterized by overshooting, global neutrophil activation in severe disease. a, 
Neutrophil count of COVID-19 patients from white blood cell differential. N=19 CoV_int, n=10 
CoV_sev, two-tailed unpaired Student’s t-test. Reference range for neutrophil counts is shown in 








of patients at blood draw. n=19 CoV_int, n=10 CoV_sev. c-f, t-Distributed Stochastic Neighbor 
Embedding (t-SNE) of neutrophil heterogeneity panel of Ctrl, Ctrl_pneu, CoV_int and CoV_sev 
(n=25,000 down-sampled cells per group). n=7 Ctrl, n=4 Ctrl_pneu, n=11 CoV_int, n=5 
CoV_sev patients. c, t-SNE plot d, t-SNE density plot displaying polarization of each group. e, 
Color-coded phenograph-based sub-clusters of the t-SNE plot are shown. f, Heatmap of the mean 
fluorescence intensity (MFI) for neutrophil sub-clusters relative to the maximum MFI. See 
Methods for the exact clustering of the heatmap. For PMN 3 and PMN 6 the percentages of total 
neutrophils of each patient within this sub-cluster are annotated in violin plots. Percentages of 
neutrophils in each sub-cluster are shown in gray above the heatmap. Kruskal-Wallis test and 
post-hoc Dunn`s multiple comparison test. Line denotes significant Kruskal-Wallis test, but non-
significant post-hoc test. g, Linear regression of CD177 expression of neutrophils with Horowitz 
Index. n=10 CoV_int, n=5 CoV_sev. h, Percent of activated neutrophils in COVID-19 and 
control blood assessed by citH3 and MPO membrane blebbing in 6 high-power fields per patient. 
Representative micrographs are shown on the left. n=5 controls, n=3 CoV_sev. Two-tailed 
unpaired Student’s t-test. i, Linear regression of neutrophil platelet aggregates as percentage of 
total blood leukocytes with Horowitz Index. n=10 CoV_int, n=5 CoV_sev. * p<0.05, ** p<0.01. 
 
Figure 3. High dimensional analysis of platelet markers and platelet function tests reveal a 
distinct platelet phenotype. a, Platelet count on the day of admission for intermediate (CoV_int 
n=19) and severe COVID-19 patients (CoV_sev n=7). Reference range for platelet counts is 
shown in gray (160 to 360 x1000/µl). b, Time course of platelet count (red spheres) and 
Interleukin-6 (IL-6) (white triangles) of CoV_sev patients normalized to the day of ICU 









platelet counts. c, Changes in platelet count and IL-6 measurements over time (days) in CoV_sev 
patients. Gray: reference range for platelet counts (160 to 360 x1000/µl). n=8 for PLTC, n=9 for 
IL-6. Two-tailed paired t-test. d, t-Distributed Stochastic Neighbor Embedding (t-SNE) of 
platelet heterogeneity panel of Ctrl, Ctrl_pneu, CoV_int and CoV_sev (n=40,000 down-sampled 
cells per group). e, t-SNE plot displayed separately for each group, represented as a density plot. 
f, Color-coded Phenograph platelet subclusters. g, Heatmap of the mean fluorescence intensity 
(MFI) for each platelet subcluster relative to the maximum MFI of the surface marker. See 
Methods for the exact clustering of the heatmap. For subcluster population Plt 1, 4, 9 and 10, the 
percentages of total platelets of each patient within this subcluster are annotated in violin plots. 
Percentages of platelets in each subcluster are shown in gray above the heatmap. Kruskal-Wallis 
test and a post-hoc Dunn`s multiple comparison test. Line denotes significant Kruskal-Wallis 
test, but non-significant post-hoc test. d-g: n=7 Ctrl, n=4 Ctrl_pneu, n=11 CoV_int, n=5 
CoV_sev patients. h, Platelet function analyzer-200 (PFA) results for collagen/epinephrine (EPI) 
and collagen/ADP (ADP). Gray: reference ranges for the PFA test (PFA EPI: 84-160s PFA 
ADP: 68-121s). n=9 CoV_int, n=8 CoV_sev, two-tailed unpaired Student’s t-test. i, Whole blood 
impedance aggregometry (Multiplate®, MP) results for thrombin-receptor agonist peptide 
(TRAP) and adenosine diphosphate (ADP) stimulation. Gray: reference ranges for the MP test 
(MP TRAP: 76-154U, MP ADP: 53-122U).  n=9 CoV_int, n=8 CoV_sev. * p<0.05, ** p<0.01, 
*** p<0.001. 
Figure 4. A systemic procoagulant state and Neutrophil extracellular trap (NET) formation 
in COVID-19. a, International normalized ratio (INR) and activated partial thromboplastin time 








in gray (INR: 0.8-1.2, aPTT 22-34s), n=19 CoV_int, n=11 CoV_sev. b, Fibrinogen (Clauss) 
plasma levels of COVID-19 patients at time of blood draw. Reference ranges are shown in gray 
(210-400mg/dl), n=20 CoV_int, n=11 CoV_sev. c, Linear regression of fibrinogen plasma level 
and Horowitz Index (paO2/FiO2) of COVID-19 patients. n=19 CoV_int (orange), n=11 CoV_sev 
(red). d, D-Dimer plasma levels of COVID-19 patients. Reference ranges are shown in gray 
(<0.5 µg/ml), n=20 CoV_int, n=11 CoV_sev. e ExTEM and InTEM Maximum Clot Firmness 
(MCF). Reference ranges are shown in gray (ExTEM 50-72 mm, InTEM 50-72 mm). f, ExTEM 
and InTEM Clot Formation Time (CFT). Reference ranges are shown in gray (ExTEM 34-159 
mm, InTEM 30-110 mm), g, Linear regression of InTEM MCF and Horowitz Index. h, ExTEM 
maximum lysis (ML). Reference ranges are shown in gray (<15%), i, Linear regression of 
ExTEM ML and Horowitz Index. j, FibTEM MCF, Reference ranges are shown in gray (9-25 
mm). k, Linear regression of FibTEM MCF and Fibrinogen plasma levels. e-k: CoV_int n=9 and 
CoV_sev n=8. e,f,h,j: Two-tailed unpaired Student’s t-test. l, Schematic of the PRP-stimulation 
assay. m, Representative micrograph of platelets isolated from a CoV_sev patient binding to a 
neutrophil undergoing NETosis in vitro and quantification of control or COVID-19 platelets 
associated with neutrophils (see l). Scale bar: 10 µm. n, Representative micrographs and 
quantification of NETs formed by neutrophils stimulated with control or COVID-19 PRP (see l). 
Scale bar: 20µm. m-n: n=3 COVID-19 patients, n=5 controls. Two-tailed unpaired Student’s t-
test. o, Immunofluorescence staining of a representative COVID-19 lung autopsy specimen. 
Arrow: activated neutrophil, Stars: Neutrophil extracellular traps. top right: 3D reconstruction if 
NETing neutrophil, Arrow indicates citH3 and DNA signal in MPO+ NET structure. Bottom 
right: pseudocolored Fibrinogen co-staining. Scale bar: 10 µm, dashed lines indicate vessel 









COVID-19 patients, n=5 controls. Two-tailed unpaired t-test with Welch’s correction. q, 
Immunofluorescence staining of COVID-19 autopsy specimens of the lung, kidney and heart. 
Top: Staining for neutrophils (Myeloperoxidase, MPO), DNA, and citrullinated Histone H3 
(citH3). Rectangless show areas of interest with NET-like structures in all three organs that are 
enlarged in Fig. 4r. Bottom: Fibrinogen staining is pseudocolored. Scale bar: 10 µm, dashed lines 
indicate vessel borders. r, Enlarged areas from q with NET-like structures (arrows). Scale bar: 10 
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